Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Futurefeed Pty Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action defines the current prosecution landscape for the company. The focus on Biotechnology & Pharmaceuticals indicates that the company is pursuing protection for complex biological or chemical innovations. Practitioners should note that the technical scope is limited to this specific technology area.
The pending office action is assigned to 1 distinct examiner and a distinct art unit. The alignment of the action with a distinct examiner and 1 distinct art unit suggests a highly centralized examination process. There is no fragmentation of the portfolio across different departments, which can often lead to more consistent prosecution outcomes. This structure allows for a focused strategy within the specific art unit involved.
JAVANMARD, SAHAR is the busiest examiner, handling the busiest examiner pending action. Since there is only a distinct examiner for the entire portfolio, JAVANMARD, SAHAR is the sole point of contact for the company's current USPTO matters. This centralization allows for a direct interaction model. Practitioners can dedicate their efforts to the specific requirements of JAVANMARD, SAHAR to resolve the pending office action. The reliance on a single examiner and art unit simplifies the procedural landscape.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JAVANMARD, SAHAR | 1 | 64.9% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837062 | NOVEL COMPOSITIONS FOR REDUCING METHANE PRODUCTION IN RUMINANT ANIMALS | JAVANMARD, SAHAR | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837062 | NOVEL COMPOSITIONS FOR REDUCING METHANE PRODUCTION IN RUMINANT ANIMALS | JAVANMARD, SAHAR | 1622 | §103 | Non-Final OA | — | Pending | Aug 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFuturefeed Pty Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sahar Javanmard has the most, with 1 of Futurefeed Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
